Buyers eye Relypsa and its hyperkalemia drug

Eric Palmer Redwood City, CA-based Relypsa has hired an investment bank to check out M&A offers, Reuters reported. Relypsa isn't commenting but the news service says several ...

Relypsa pitches $126M IPO as lead CKD drug nears moment of PhIII truth

John Carroll Just weeks away from reporting key endpoint data from a Phase III trial of its lead therapy, Relypsa has mapped out plans to go public, shooting for a $ 126.5 million ...
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS